E Vanmechelen

Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke.

K. Blennow, H. Vanderstichele, E. Vanmechelen, 2000, Journal of Alzheimer's disease : JAD.

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

K. Blennow, B. Winblad, H. Vanderstichele, 2001, Archives of neurology.

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

K. Blennow, B. Winblad, H. Vanderstichele, 1999, Archives of neurology.

Cerebrospinal beta-amyloid (1–42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline

H. Vanderstichele, A. Kurz, M. Riemenschneider, 2000, Neuroscience Letters.

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study

K. Blennow, B. Winblad, E. Vanmechelen, 1998, Journal of neurology, neurosurgery, and psychiatry.